Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

NCT01765803 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Primary objective not met after planned interim analysis

Conditions

Healthy Subjects

Interventions

DRUG: Mellaril

Sponsor

New Mexico Cancer Research Alliance

Collaborators

[object Object]